TNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy
Tumor necrosis factor superfamily member 14 (LIGHT) has been in pre-clinical development for over a decade and shows promise as a modality of enhancing treatment approaches in the field of cancer immunotherapy. To date, LIGHT has been used to combat cancer in multiple tumor models where it can be co...
Main Authors: | Joseph G. Skeate, Mikk E. Otsmaa, Ruben Prins, Daniel J. Fernandez, Diane M. Da Silva, W. Martin Kast |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-05-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.00922/full |
Similar Items
-
LIGHT/TNFSF14 Affects Adipose Tissue Phenotype
by: Angela Oranger, et al.
Published: (2024-01-01) -
Molecular and Clinical Characterization of LIGHT/TNFSF14 Expression at Transcriptional Level via 998 Samples With Brain Glioma
by: Ying Yang, et al.
Published: (2021-08-01) -
Dissecting Abdominal Aortic Aneurysm Is Aggravated by Genetic Inactivation of LIGHT (TNFSF14)
by: Andrea Herrero-Cervera, et al.
Published: (2021-10-01) -
Tumor Necrosis Factor Superfamily 14 (LIGHT) Restricts Neovascularization by Decreasing Circulating Endothelial Progenitor Cells and Function
by: Chien-Yi Hsu, et al.
Published: (2023-04-01) -
LIGHT/TNFSF14 as a New Biomarker of Bone Disease in Multiple Myeloma Patients Experiencing Therapeutic Regimens
by: Giacomina Brunetti, et al.
Published: (2018-10-01)